Shares of OptiNose Inc (NASDAQ:OPTN) have earned an average broker rating score of 1.25 (Strong Buy) from the four brokers that cover the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a buy rating and three have given a strong buy rating to the company. OptiNose’s rating score has improved by 6% from three months ago as a result of various analysts’ ratings changes.
Brokerages have set a 1-year consensus price objective of $29.25 for the company and are expecting that the company will post ($0.46) EPS for the current quarter, according to Zacks. Zacks has also given OptiNose an industry rank of 205 out of 265 based on the ratings given to its competitors.
Separately, Piper Jaffray Companies set a $28.00 price target on OptiNose and gave the company a “buy” rating in a research report on Monday, January 15th.
A number of large investors have recently bought and sold shares of OPTN. California State Teachers Retirement System acquired a new position in OptiNose during the fourth quarter valued at $162,000. TIAA CREF Investment Management LLC acquired a new position in OptiNose during the fourth quarter valued at $173,000. Teachers Advisors LLC acquired a new position in OptiNose during the fourth quarter valued at $184,000. Millennium Management LLC acquired a new position in OptiNose during the fourth quarter valued at $190,000. Finally, Deutsche Bank AG acquired a new position in OptiNose during the fourth quarter valued at $247,000. 29.36% of the stock is currently owned by hedge funds and other institutional investors.
OptiNose, Inc is a pharmaceutical company. The Company is focused on the development and commercialization of products for patients treated by ear, nose and throat, or ENT, and allergy specialists. The Company’s products candidates include XHANCE (Nasal Polyps), XHANCE (Chornic Sinusitis) OPN-300, OPN-021, and other.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for OptiNose Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptiNose and related companies with MarketBeat.com's FREE daily email newsletter.